Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | CALCA | P06881 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817596 | 0.80 | PTPRC (0.50) | PTPRCL3MBTL1MAPTALDH1A1 | |
| SCHEMBL27903118 | 0.72 | KDM4E (0.40) | KDM4EMAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1843561 | 0.70 | ALDH1A1 (0.49) | KDM4EL3MBTL1MTNR1AMTNR1BMAPT | |
| SCHEMBL26566722 | 0.69 | USP30 (0.53) | PTPRCALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL31724800 | 0.69 | USP30 (0.53) | PTPRCALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4812280 | 0.69 | AKR1C3 (0.45) | KDM4EMAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL16116065 | 0.69 | EED (0.57) | — | |
| SCHEMBL7842881 | 0.68 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2POLBHSD17B10 | |
| SCHEMBL30572070 | 0.67 | KMT2A (0.56) | PTPRCL3MBTL1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL20451400 | 0.66 | TGM2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | PTPRC 336/4885CALCA 4703/4885KDM4E 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.